| Medical and Health Sciences | Lifetime | 573 | FR 8 | 99.97 |
| Epidemiology | Lifetime | 63 | FR 4 | 99.89 |
| Critical Care and Intensive Care Medicine | Lifetime | 8 | FR 1 | 99.91 |
| Emergency Medical Services | Lifetime | 117 | FR 1 | 98.76 |
| Pulmonary and Respiratory Medicine | Lifetime | 624 | FR 33 | 99.09 |
| Infectious Diseases | Lifetime | 488 | FR 27 | 98.12 |
| Molecular Medicine | Lifetime | 117 | FR 7 | 97.12 |
| Applied Microbiology and Biotechnology | Lifetime | 46 | FR 2 | 96.93 |
| Emergency Medicine | Lifetime | 452 | FR 10 | 95.93 |
| Epidemiology | 2021-2025 | 222 | FR 7 | 98.36 |
| Critical Care and Intensive Care Medicine | 2021-2025 | 24 | FR 3 | 98.06 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 516 | FR 32 | 94.33 |
| Infectious Diseases | 2021-2025 | 548 | FR 23 | 87.91 |
| Pneumonia and Respiratory Infections | Lifetime | 1 | FR 1 | 99.95 |
| Nosocomial Infections in ICU | Lifetime | 3 | FR 1 | 99.95 |
| Respiratory Support and Mechanisms | Lifetime | 38 | FR 2 | 99.83 |
| Sepsis Diagnosis and Treatment | Lifetime | 41 | FR 4 | 99.74 |
| Antibiotic Resistance in Bacteria | Lifetime | 67 | FR 6 | 99.72 |
| Antibiotic Use and Resistance | Lifetime | 28 | FR 2 | 99.69 |
| Emergency and Acute Care Studies | Lifetime | 69 | FR 1 | 99.28 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 72 | FR 6 | 99.42 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 137 | FR 4 | 99.19 |
| Respiratory viral infections research | Lifetime | 196 | FR 2 | 99.13 |
| Intensive Care Unit Cognitive Disorders | Lifetime | 151 | FR 12 | 99.02 |
| COVID-19 Clinical Research Studies | Lifetime | 445 | FR 22 | 98.24 |
| Central Venous Catheters and Hemodialysis | Lifetime | 234 | FR 9 | 98.22 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 307 | FR 20 | 98.35 |
| Long-Term Effects of COVID-19 | Lifetime | 607 | FR 33 | 95.81 |
| Airway Management and Intubation Techniques | Lifetime | 414 | FR 38 | 97.39 |
| Influenza Virus Research Studies | Lifetime | 518 | FR 13 | 97.71 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 462 | FR 25 | 97.94 |
| Inhalation and Respiratory Drug Delivery | Lifetime | 338 | FR 7 | 97.44 |
| Antifungal resistance and susceptibility | Lifetime | 595 | FR 33 | 97.10 |
| Healthcare Decision-Making and Restraints | Lifetime | 202 | FR 2 | 95.77 |
| Hemodynamic Monitoring and Therapy | Lifetime | 946 | FR 61 | 95.59 |
| Nosocomial Infections in ICU | 2021-2025 | 7 | FR 3 | 99.36 |
| Pneumonia and Respiratory Infections | 2021-2025 | 28 | FR 4 | 99.01 |
| Antibiotic Use and Resistance | 2021-2025 | 52 | FR 3 | 98.37 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 351 | FR 31 | 94.25 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 177 | FR 12 | 94.10 |
| Long-Term Effects of COVID-19 | 2021-2025 | 962 | FR 39 | 93.10 |
| Respiratory Support and Mechanisms | 2021-2025 | 471 | FR 46 | 94.99 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 421 | FR 32 | 93.71 |
| Inhalation and Respiratory Drug Delivery | 2021-2025 | 169 | FR 5 | 92.13 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 398 | FR 16 | 89.79 |
| Neutropenia and Cancer Infections | 2021-2025 | 405 | FR 27 | 79.81 |
| Antifungal resistance and susceptibility | 2021-2025 | 894 | FR 43 | 85.12 |
| Healthcare Systems and Challenges | 2021-2025 | 300 | FR 5 | 40.63 |
